Amgen Ventures, Brace Pharma Capital and Alexandria Venture Investments all invested in the genome editing technology provider.

US-based genomic medicine developer Precision BioSciences completed a $110m series B round yesterday that included pharmaceutical firms Amgen and EMS, and real estate investment trust Alexandria Real Estate Equities.

Franklin Templeton Investments, Cowen Healthcare Investments, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Ridgeback Capital, Agent Capital, VenBio, F-Prime, RA Capital Management, Osage University Partners, Duke Management Company, Longevity Fund and entities affiliated with Leerink Partners also invested.

The corporates participated through their respective…